Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma
Zanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs acalabrutinib and ibrutinib in 1L and 2L.
Authors
- Wesley Furnback (ORCID: https://orcid.org/0000-0001-5532-9688)
- Kaitlyn Esselman (ORCID: https://orcid.org/0000-0002-5721-665X)
- Swetha Challagulla
- Elizabeth Wu
- Mei Xue
- Javier Pinilla-Ibarz
- Keri Yang
Institutions
- National University of Misiones (AR)
- Moffitt Cancer Center (US)
- Universidad Real (BO)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1080/17474086.2026.2628549
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00